<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the efficacy and safety of the association of repaglinide, <z:chebi fb="0" ids="6801">metformin</z:chebi> and bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin compared to two classic regimens: <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> and two doses of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> in patients with poorly controlled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> despite two or more oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs (OADs) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Random, parallel and open study of 24 weeks with 37 patients randomized into three therapeutic groups: group A (n=12) (repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>), group B (n=12) (<z:chebi fb="0" ids="6801">metformin</z:chebi>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>) and group C (n=13) (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The insulin was adjusted in the visits to obtain a basal blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;110 mg/dl </plain></SENT>
<SENT sid="3" pm="."><plain>The endpoint criteria included HbA1c, blood <z:chebi fb="105" ids="17234">glucose</z:chebi> profile, <z:hpo ids='HP_0001943'>hypoglycemias</z:hpo> and body weight </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At the end of the study, group A presented HbA1c (mean+/-standard deviation) 7.2+/-0.7%, which was significantly less than B (8.8+/-0.1%) and C (8.4+/-1.2%) </plain></SENT>
<SENT sid="5" pm="."><plain>In terms of absolute reduction, there were only differences (p=0.01) between group A (-2.4+/-1.1%) and B (-0.7+/-1.2%) </plain></SENT>
<SENT sid="6" pm="."><plain>Group A presented lower postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> values (p&lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Nor were there any significant differences in <z:mp ids='MP_0005456'>weight gain</z:mp> and incidence of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The combination of repaglinide, <z:chebi fb="0" ids="6801">metformin</z:chebi> and bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> is safe and effective and it provides better postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="9" pm="."><plain>The association of <z:chebi fb="0" ids="6801">metformin</z:chebi> and a dose of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> does not obtain suitable control in patients with a long evolution who have already received two or more OADs </plain></SENT>
</text></document>